Waters Corporation (WAT) has experienced notable market movements, performing both under and above competitors on different occasions. The firm has reported its Q2 2024 financial results and faced varying levels of Wall Street optimism and skepticism. Despite market irregularities and an EPS aligning with projections amidst a sales decline, WAT's stock has seen an upgrade with a target raise to $389. Notably, the company appointed Heather Knight to its Board of Directors and announced its engagement in accelerating the development of gene-based therapeutics. However, WAT lowered its profit forecast citing reduced demand, showing the firm’s susceptibility to headwinds despite delivering earnings and sales beat in Q2. The company has made strides in the RNA-based vaccines and therapies area, and innovative quality control testing with the launch of its Discovery Core Rheometer. Waters Corp. concluded several important partnerships, like the collaboration with the University of San Agustin to establish the Philippines' first Mass Spectrometry Imaging Center, and obtained rights to mass spectrometry imaging, securing a strong future position in the market.
Waters Corp WAT News Analytics from Fri, 04 Mar 2011 08:00:00 GMT to Sat, 26 Oct 2024 16:35:51 GMT -
Rating 4
- Innovation 5
- Information 8
- Rumor -2
